Endocrine

, Volume 59, Issue 1, pp 209–212 | Cite as

Expression of YAP1 in aggressive thyroid cancer

  • Marilena Celano
  • Chiara Mignogna
  • Francesca Rosignolo
  • Marialuisa Sponziello
  • Michelangelo Iannone
  • Saverio Massimo Lepore
  • Giovanni Enrico Lombardo
  • Valentina Maggisano
  • Antonella Verrienti
  • Stefania Bulotta
  • Cosimo Durante
  • Carla Di Loreto
  • Giuseppe Damante
  • Diego Russo
Research Letter
  • 193 Downloads

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    F.X. Yu, B. Zhao, K.L. Guan, Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163(4), 811–828 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    K.F. Harvey, X. Zhang, D.M. Thomas, The hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013)CrossRefPubMedGoogle Scholar
  3. 3.
    A.A. Steinhardt, M.F. Gayyed, A.P. Klein, J. Dong, A. Maitra, D. Pan, E.A. Montgomery, R.A. Anders, Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 39, 1582–1589 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    L. Guo, L. Teng, YAP/TAZ for cancer therapy: opportunities and challenge. Int. J. Oncol. 46, 1444–1452 (2015)CrossRefPubMedGoogle Scholar
  5. 5.
    S.E. Lee, J.U. Lee, M.H. Lee, M.J. Ryu, S.J. Kim, Y.K. Kim, M.J. Choi, K.S. Kim, J.M. Kim, J.W. Kim, Y.W. Koh, D.S. Lim, Y.S. Jo, M. Shong, RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis 2, e55 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    M.E. Garcia-Rendueles, J.C. Ricarte-Filho, B.R. Untch, I. Landa, J.A. Knauf, F. Voza, V.E. Smith, I. Ganly, B.S. Taylor, Y. Persaud, G. Oler, Y. Fang, S.C. Jhanwar, A. Viale, A. Heguy, K.H. Huberman, F. Giancotti, R. Ghossein, J.A. Fagin, NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. Cancer Discov. 5(11), 1178–1193 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G. Randolph, A. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    M. Sponziello, C. Durante, A. Boichard, M. Dima, C. Puppin, A. Verrienti, G. Tamburrano, G. Di Rocco, A. Redler, L. Lacroix, J.M. Bidart, M. Schlumberger, G. Damante, D. Russo, S. Filetti, Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol. Cell. Endocrinol. 392, 8–13 (2014)CrossRefPubMedGoogle Scholar
  9. 9.
    C. Mignogna, N. Staropoli, C. Botta, C. De Marco, A. Rizzuto, M. Morelli, A. Di Cello, R. Franco, C. Camastra, I. Presta, N. Malara, A. Salvino, P. Tassone, P. Tagliaferri, T. Barni, G. Donato, A. Di Vito, Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J. Ovarian Res. 9(1), 31 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    M. Sponziello, A. Verrienti, F. Rosignolo, R.F. De Rose, V. Pecce, V. Maggisano, C. Durante, S. Bulotta, G. Damante, L. Giacomelli, C.R. Di Gioia, S. Filetti, D. Russo, M. Celano, PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine 50(2), 434–441 (2015)CrossRefPubMedGoogle Scholar
  11. 11.
    M. Schlumberger, L. Lacroix, D. Russo, S. Filetti, J.M. Bidart, Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat. Clin. Pract. Endocrinol. Metab. 3, 260–269 (2007)CrossRefPubMedGoogle Scholar
  12. 12.
    M.E. Cabanillas, D.G. McFaddek, C. Durante, Thyroid Cancer. Lancet 388, 2783–2795 (2016)Google Scholar
  13. 13.
    S. Jin, O. Borkhuu, W. Bao, Y.T. Yang, Signaling pathways in thyroid cancer and their therapeutic implications. J. Clin. Med. Res. 8(4), 284–296 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    S. Bulotta, M. Celano, G. Costante, D. Russo, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52, 214–221 (2016)CrossRefPubMedGoogle Scholar
  15. 15.
    R. Abylkassov, Y. Xie, Role of yes-associated protein in cancer: An update. Oncol. Lett. 12(4), 2277–2282 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    M. Yuan, V. Tomlison, R. Lara, D. Holliday, C. Chelala, T. Harada, R. Gangeswaran, C. Manson-Bishop, P. Smith, S.A. Danovi, O. Pardo, T. Crook, C.A. Mein, N.R. Lemoine, L.J. Jones, S. Basu, Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell. Death Differ. 15, 1752–1759 (2008)CrossRefPubMedGoogle Scholar
  17. 17.
    C. Ugolini, N. Borrelli, C. Niccoli, R. Elisei, D. Viola, P. Vitti, P. Miccoli, F. Basolo, Role of YAP-1 in thyroid tumor progression and outcome. Appl. Immunohistochem. Mol. Morphol. [epub ahead of print] Oct 7 (2016)Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Marilena Celano
    • 1
  • Chiara Mignogna
    • 1
  • Francesca Rosignolo
    • 2
  • Marialuisa Sponziello
    • 2
  • Michelangelo Iannone
    • 3
  • Saverio Massimo Lepore
    • 1
  • Giovanni Enrico Lombardo
    • 1
  • Valentina Maggisano
    • 1
  • Antonella Verrienti
    • 2
  • Stefania Bulotta
    • 1
  • Cosimo Durante
    • 2
  • Carla Di Loreto
    • 4
  • Giuseppe Damante
    • 4
  • Diego Russo
    • 1
  1. 1.Department of Health Sciences“Magna Graecia” University of CatanzaroCatanzaroItaly
  2. 2.Department of Internal Medicine and Medical Specialties“Sapienza” University of RomeRomeItaly
  3. 3.CNRInstitute of Neurological SciencesBorgiaItaly
  4. 4.Department of Medical and Biological SciencesUniversity of UdineUdineItaly

Personalised recommendations